Please ensure Javascript is enabled for purposes of website accessibility

The Effects Of Copycat Drugs on Novartis, Merck, and Eli Lilly

By Peter Stephens – Feb 7, 2014 at 5:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novartis, Merck, and Eli Lilly are all being challenged by low-cost generic drugs. How are they coping with the problem?

A key theme of fourth-quarter earnings reports from major drug companies has been the challenge of generic competition, with the result being lower sales and lower profit for many global pharmaceutical stocks.

Eli Lilly (LLY 0.28%) is a prime example of this, reporting a decline of 12% in fourth-quarter revenue. This was mainly the result of Lilly losing patent protection for its most important product, the antidepressant Cymbalta, which has led to the introduction of a number of lower cost copies.

In addition, Eli Lilly could as soon as March lose patent protection for its bone-building drug Evista, with other product facing the same situation through 2014. So sales could be pinned back somewhat during the year.

However, generic competition did not seem to impact fourth-quarter results from Novartis (NVS 0.10%). It posted a 2% increase in quarterly net profit and actually benefited from positive surprises with regard to generic competition.

Unlike many of its peers, Novartis did not experience the level of competition from generics that it had expected. As such, sales increased by 3% from the fourth quarter of 2012.

That's not to say that Novartis avoided generic competition entirely, but it did get a little bit more breathing space in which to counter lower-cost copies.

Indeed, there were multiple key developments concerning Novartis' product pipeline during the fourth quarter, including regulatory approval for a pre-filled syringe for diabetic macular edema drug Lucentis in Europe and Australia, as well a positive recommendation in the U.K. and Germany for Jetrea, which is used in treating symptomatic vitreomacular adhesion and vitreomacular traction when associated with macular hole.

Novartis has also delivered multiple regulatory filings, which appears to further strengthen the company's position for 2014. Company guidance states that the top line is set to grow at low to mid single-digits, with the bottom line benefiting from improved efficiencies to grow at a slightly faster rate.

Meanwhile, sector peer Merck (MRK 0.79%) was able to increase earnings per share by 6% in the fourth quarter of 2013 from the year-ago period despite suffering from a significant amount of generic competition. Its top line fell by 4% in the quarter as drugs such as Singulair, Maxalt, and Temodar lost market exclusivity, although much of the decline was offset by strong sales growth for a number of other drugs, including Remicade and Simponi.

Clearly, Merck is adapting to increased challenges from generics, although it does have a relatively strong pipeline and is anticipating regulatory actions for a number of drugs in 2014, including Vorapaxar (for the reduction of atherothrombotic events) and Noxafil IV (for fungal infections). Although lower-cost generics hit sales growth during the quarter, Merck seemed better able to cope with the challenge than Eli Lilly.

Of course, Eli Lilly does have multiple drugs within its pipeline and recently submitted four new products for approval, so while challenges remain to key products, it appears the company can turn things around over the medium to long term.

While Novartis looks to be the best placed for 2014 in terms of how it coped with generic competition in 2013, Merck and Eli Lilly could yet surprise on the upside.

Peter Stephens has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co. Stock Quote
Merck & Co.
MRK
$108.35 (0.79%) $0.85
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$366.25 (0.28%) $1.00
Novartis Stock Quote
Novartis
NVS
$87.80 (0.10%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.